Advertisement

Clinical Drug Investigation

, Volume 39, Issue 8, pp 805–819 | Cite as

Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

  • Katherine A. Lyseng-WilliamsonEmail author
Adis Disease Management

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established as effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as monotherapy or in combination with oral glucose-lowering drugs ± insulin. The six subcutaneous GLP-1RA formulations (i.e. twice-daily exenatide, once-daily liraglutide and lixisenatide, and once-weekly dulaglutide, exenatide and semaglutide) currently available in the EU and USA have many similarities, but also some unique features and properties. By stimulating GLP-1 receptors, GLP-1RAs increase insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving clinical and patient-reported outcomes related to glycaemic control and weight. They also have been shown to reduce, or at least not increase, the risk of major cardiovascular outcomes. GLP-1RAs are generally well tolerated, with gastrointestinal and injection-site reactions being the most troublesome drug-related adverse events, and are associated with a very low intrinsic risk of hypoglycaemia. Treatment with GLP-1RAs should be customized to meet the clinical needs and personal preferences of the individual.

Notes

Acknowledgements

The author thanks Prof. John Wilding, Obesity & Endocrinology Research, Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UK for his assistance in preparing this review.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K.A. Lyseng-Williamson is an employee of Adis International/Springer Nature, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Brussels: International Diabetes Federation; 2017.Google Scholar
  2. 2.
    American Diabetes Association. 9. Pharmacological approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S90–102.CrossRefGoogle Scholar
  3. 3.
    Ahren B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig. 2018.  https://doi.org/10.1111/jdi.12911.Google Scholar
  4. 4.
    Byetta (exenatide) solution for injection in prefilled-pen: EU summary of product characteristics. Södertälje: AstraZeneca AB; 2018.Google Scholar
  5. 5.
    Byetta (exenatide) injection: US prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
  6. 6.
    Victoza (liraglutide) 6 mg/ml solution for injection in pre-filled pen: EU summary of product characteristics. Bagsværd: Novo Nordisk A/S; 2018.Google Scholar
  7. 7.
    Victoza (liraglutide) injection, for subcutaneous use: US prescribing information. Plainsboro: Novo Nordisk Inc.; 2018.Google Scholar
  8. 8.
    Lyxumia (lixisenatide) 10 and 20 micrograms solution for injection: EU summary of product characteristic. Paris: Sanofi-aventis Groupe; 2017.Google Scholar
  9. 9.
    Adlyxin (lixisenatide) injection, for subcutaneous use: US prescribing information. Bridgewater Sanofi-Aventis U.S. LLC; 2019.Google Scholar
  10. 10.
    Trulicity (dulaglutide) 0.75 and 1.5 mg solution for injection in pre-filled pen: EU summary of product characteristics. Utrecht: Eli Lilly Nederland B.V.; 2018.Google Scholar
  11. 11.
    Trulicity (dulaglutide) injection for subcutaneous use: US prescribing information. Indianapolis: Eli Lilly and Company; 2019.Google Scholar
  12. 12.
    Bydureon 2 mg prolonged-release suspension for injection ([powder and solvent; pre-filled pen and BCise): EU summary of product characteristics. Södertälje (Sweden): AstraZeneca AB; 2019.Google Scholar
  13. 13.
    Bydureon® (exenatide extended-release) for injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
  14. 14.
    Bydureon® BCise™ (exenatide extended-release) injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2019.Google Scholar
  15. 15.
    Ozempic (semagutide) 0.25, 0.5 and 1 mg solution for injection in pre-filled pen: EU summary of product characteristics. Bagsværd: Novo Nordisk A/S; 2018.Google Scholar
  16. 16.
    Ozempic (semaglutide) injection 0.5 mg/1 mg: US prescribing information. Plainsboro: Novo Nordisk Inc.; 2017.Google Scholar
  17. 17.
    Sposito AC, Berwanger O, de Carvalho LSF, et al. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157.  https://doi.org/10.1186/s12933-018-0800-2.CrossRefGoogle Scholar
  18. 18.
    Sharma D, Verma S, Vaidya S, et al. Recent updates on GLP-1 agonists: current advancements and challenges. Biomed Pharmacother. 2018;108:952–62.CrossRefGoogle Scholar
  19. 19.
    Gentilella R, Pechtner V, Corcos A, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35:e3070.  https://doi.org/10.1002/dmrr.3070.CrossRefGoogle Scholar
  20. 20.
    Sfairopoulos D, Liatis S, Tigas S, et al. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens). 2018;17(3):333–50.CrossRefGoogle Scholar
  21. 21.
    Sun F, Wu S, Gou S, et al. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine. 2015;48(3):794–803.CrossRefGoogle Scholar
  22. 22.
    Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317–32.CrossRefGoogle Scholar
  23. 23.
    Hitke ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36.CrossRefGoogle Scholar
  24. 24.
    Unni S, Wittbrodt E, Ma J, et al. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):468–73.CrossRefGoogle Scholar
  25. 25.
    Yu M, Van Brunt K, Varnado OJ, et al. Patient-reported outcome. Results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18(4):419–24.CrossRefGoogle Scholar
  26. 26.
    Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009;26(7):722–8.CrossRefGoogle Scholar
  27. 27.
    Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34(2):314–9.CrossRefGoogle Scholar
  28. 28.
    Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–301.CrossRefGoogle Scholar
  29. 29.
    Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.CrossRefGoogle Scholar
  30. 30.
    Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66.CrossRefGoogle Scholar
  31. 31.
    Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2017.  https://doi.org/10.2337/dc17-0417.Google Scholar
  32. 32.
    Pratley R, Aroda V, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86.CrossRefGoogle Scholar
  33. 33.
    Uusinarkaus K, Rodbard HW, Van Gaal L, et al. Semaglutide-induced weight loss is associated with improved health-related quality of life and treatment satisfaction [abstract no. 1020-P]. Diabetes. 2019;68 (Suppl 1).  https://doi.org/10.2337/db19-1020-P.
  34. 34.
    Giorgino F, Penformis A, Pechtner V, et al. Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Prefer Adherence. 2018;12:707–19.CrossRefGoogle Scholar
  35. 35.
    Nguyen H, Dufour R, Caldwell-Tarr A. Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population. Adv Ther. 2017;34(3):658–73.CrossRefGoogle Scholar
  36. 36.
    Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119–33.CrossRefGoogle Scholar
  37. 37.
    Qaio Q, Ouwens MJ, Grandy S, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201–5.CrossRefGoogle Scholar
  38. 38.
    Alatorre C, Fernández Landó L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953–61.CrossRefGoogle Scholar
  39. 39.
    Heile M, Wyne K, Billings LK, et al. Cardiovascular outcomes with once-weekly GLP-1 RAs: clinical and economic implications. J Manag Care Spec Pharm. 2018;24(9-a):S42–52.Google Scholar
  40. 40.
    Bahtiyar G, Pujais-Kury J, Sacerdote A. Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes. Curr Diabetes Rep. 2018;18(10):92.  https://doi.org/10.1007/s11892-018-1043-z.CrossRefGoogle Scholar
  41. 41.
    Li Y, Rosenbilt PD. Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect? Curr Cardiol Rep. 2018;20(11):113.  https://doi.org/10.1007/s11886-018-1051-2.CrossRefGoogle Scholar
  42. 42.
    Torekov SS. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Cardiovasc Res. 2018;114(10):e70–1.CrossRefGoogle Scholar
  43. 43.
    Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRefGoogle Scholar
  44. 44.
    Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;1:1.  https://doi.org/10.1016/S0140-6736(19)31149-3.Google Scholar
  45. 45.
    Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.CrossRefGoogle Scholar
  46. 46.
    Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.CrossRefGoogle Scholar
  47. 47.
    Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.CrossRefGoogle Scholar
  48. 48.
    Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13.CrossRefGoogle Scholar
  49. 49.
    Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–30.CrossRefGoogle Scholar
  50. 50.
    Handelsman Y, Wyne K, Cannon A, et al. Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists. J Manag Care Spec Pharm. 2018;24(9-a):S14–29.Google Scholar
  51. 51.
    Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019;10:5–19.CrossRefGoogle Scholar
  52. 52.
    Sun F, Yu K, Yang Z, et al. Impact of GLP-1 receptors agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res. 2012;2012:230624.CrossRefGoogle Scholar
  53. 53.
    Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–67.CrossRefGoogle Scholar
  54. 54.
    Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145–54.CrossRefGoogle Scholar
  55. 55.
    Monami M, Nreu A, Scatena S, et al. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. J Endocrinol Investig. 2017;40(11):1251–8.CrossRefGoogle Scholar
  56. 56.
    Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26–37.CrossRefGoogle Scholar
  57. 57.
    Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2019;20(4):889–97.CrossRefGoogle Scholar
  58. 58.
    Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933–41.CrossRefGoogle Scholar
  59. 59.
    Pang B, Zhou H, Kuang H. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy. Peptides. 2018;100:123–6.CrossRefGoogle Scholar
  60. 60.
    Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225–41.CrossRefGoogle Scholar
  61. 61.
    Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptors on renal function. World J Diabetes. 2013;4(5):190–201.CrossRefGoogle Scholar
  62. 62.
    Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.CrossRefGoogle Scholar
  63. 63.
    Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271–84.CrossRefGoogle Scholar
  64. 64.
    Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):107–15.CrossRefGoogle Scholar
  65. 65.
    Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–24.CrossRefGoogle Scholar
  66. 66.
    Kayaniyil S, Lozano-Ortega G, Bennet HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther. 2016;7(1):27–43.CrossRefGoogle Scholar
  67. 67.
    Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–57.CrossRefGoogle Scholar
  68. 68.
    Xultophy (insulin degludec 100 units/mL + liraglutide 3.6 mg/mL) solution for injection in pre-filled pen: EU summary of product characteristics. Bagsværd: Novo Nordisk A/S; 2018.Google Scholar
  69. 69.
    Xultophy 110/3.6 (insulin degludec and liraglutide injection), for subcutaneous use: US prescribing information. Plainsboro: Novo Nordisk Inc.; 2019.Google Scholar
  70. 70.
    Suliqua 100/33 (insulin glargine 100 units/ml +lixisenatide 33 or 50 micrograms/ml) solution for injection in a pre-filled pen: EU summary of product characteristics. Paris: Sanofi-Aventis Groupe; 2017.Google Scholar
  71. 71.
    Soliqua 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use: US prescribing information. Bridgewater: Sanofi-Aventis U.S. LLC; 2017.Google Scholar
  72. 72.
    Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med. 2011;123(6):189–201.CrossRefGoogle Scholar
  73. 73.
    Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med. 2012;23(2):132–6.CrossRefGoogle Scholar
  74. 74.
    Brunton S. GLP-1 receptor agonists vs. DDP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557–67.CrossRefGoogle Scholar
  75. 75.
    Lee G, Oh SW, Hwang SS, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis. PLoS One. 2017;12(5):e0177646.CrossRefGoogle Scholar
  76. 76.
    Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653–64.e1.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019
corrected publication 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations